are the only affected joints. Axial disease, when present, usually occurs together with peripheral arthritis. Some patients present with rapidly progressive and destructive PsA-arthritis mutilans. PsA is associated with an adverse impact on healthrelated quality of life Both nonpharmacologic and pharmacologic treatment can ameliorate PsA symptoms and can occasionally result in disease remission (Figure 1 The presentation of PsA is heterogeneous, and health care providers frequently face challenges when considering the various treatment options. Our objective was to develop evidence-based treatment recommendations for the management of active PsA in adults, using pharmacologic and nonpharmacologic therapies. These PsA treatment recommendations can help guide both clinicians and patients to arrive at optimal management decisions. METHODS Methodology overview. This guideline followed the American College of Rheumatology (ACR) guideline development process (